Compare Procter & Gamble Health with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs IPCA LABS - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH IPCA LABS PROCTER & GAMBLE HEALTH/
IPCA LABS
 
P/E (TTM) x 51.7 22.9 225.7% View Chart
P/BV x 4.7 4.4 106.7% View Chart
Dividend Yield % 10.1 0.3 3,665.4%  

Financials

 PROCTER & GAMBLE HEALTH   IPCA LABS
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
IPCA LABS
Mar-19
PROCTER & GAMBLE HEALTH/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs3,5491,042 340.6%   
Low Rs1,301590 220.5%   
Sales per share (Unadj.) Rs511.4298.6 171.3%  
Earnings per share (Unadj.) Rs61.335.0 175.1%  
Cash flow per share (Unadj.) Rs74.049.4 149.7%  
Dividends per share (Unadj.) Rs440.003.00 14,666.7%  
Dividend yield (eoy) %18.10.4 4,935.3%  
Book value per share (Unadj.) Rs927.8247.1 375.4%  
Shares outstanding (eoy) m16.60126.35 13.1%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x4.72.7 173.5%   
Avg P/E ratio x39.623.3 169.7%  
P/CF ratio (eoy) x32.816.5 198.5%  
Price / Book Value ratio x2.63.3 79.2%  
Dividend payout %717.98.6 8,375.5%   
Avg Mkt Cap Rs m40,257103,108 39.0%   
No. of employees `0001.113.4 8.4%   
Total wages/salary Rs m1,3137,874 16.7%   
Avg. sales/employee Rs Th7,486.72,807.0 266.7%   
Avg. wages/employee Rs Th1,157.6585.8 197.6%   
Avg. net profit/employee Rs Th897.2329.0 272.7%   
INCOME DATA
Net Sales Rs m8,49037,732 22.5%  
Other income Rs m244577 42.3%   
Total revenues Rs m8,73438,309 22.8%   
Gross profit Rs m1,4826,901 21.5%  
Depreciation Rs m2111,824 11.6%   
Interest Rs m0189 0.0%   
Profit before tax Rs m1,5145,465 27.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m5631,042 54.0%   
Profit after tax Rs m1,0174,422 23.0%  
Gross profit margin %17.518.3 95.4%  
Effective tax rate %37.119.1 194.7%   
Net profit margin %12.011.7 102.2%  
BALANCE SHEET DATA
Current assets Rs m15,34323,778 64.5%   
Current liabilities Rs m1,96010,975 17.9%   
Net working cap to sales %157.633.9 464.6%  
Current ratio x7.82.2 361.3%  
Inventory Days Days49104 47.0%  
Debtors Days Days2866 43.2%  
Net fixed assets Rs m1,20920,368 5.9%   
Share capital Rs m166253 65.7%   
"Free" reserves Rs m15,23530,971 49.2%   
Net worth Rs m15,40131,224 49.3%   
Long term debt Rs m01,409 0.0%   
Total assets Rs m17,59545,507 38.7%  
Interest coverage xNM30.0-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.8 58.2%   
Return on assets %5.810.1 57.1%  
Return on equity %6.614.2 46.6%  
Return on capital %10.317.3 59.2%  
Exports to sales %045.9 0.0%   
Imports to sales %016.6 0.0%   
Exports (fob) Rs mNA17,308 0.0%   
Imports (cif) Rs mNA6,266 0.0%   
Fx inflow Rs m1,63617,308 9.5%   
Fx outflow Rs m4,3686,266 69.7%   
Net fx Rs m-2,73211,042 -24.7%   
CASH FLOW
From Operations Rs m-1,3044,923 -26.5%  
From Investments Rs m12,697-1,563 -812.3%  
From Financial Activity Rs m-301-1,832 16.4%  
Net Cashflow Rs m11,0931,528 726.1%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 11.4 159.6%  
FIIs % 1.0 25.3 4.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 17.4 167.2%  
Shareholders   28,591 36,892 77.5%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   DR. REDDYS LAB  STERLING BIOTECH  DR. DATSONS LABS  WYETH LTD  ABBOTT INDIA  

Compare PROCTER & GAMBLE HEALTH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Flat; L&T and Tech Mahindra Top Losers(12:30 pm)

Share markets in India are presently trading on a volatile note. Sectoral indices are trading mixed with stocks in the capital goods sector and realty sector.

Related Views on News

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Nov 13, 2019 12:33 PM

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 8-QTR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS